Download Files:
Evacetrapib
SKU
HY-13327-10 mg
Category Reference compound
Tags Cardiovascular Disease, CETP, Metabolic Enzyme/Protease
$150 – $1,280
Products Details
Product Description
– Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.
Web ID
– HY-13327
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C31H36F6N6O2
References
– [1]Cao G, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2011 Dec;52(12):2169-76.
CAS Number
– 1186486-62-3
Molecular Weight
– 638.65
Compound Purity
– 98.89
SMILES
– O=C([C@H]1CC[C@H](CN2CCC[C@H](N(CC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C4=NN(C)N=N4)C5=CC(C)=CC(C)=C52)CC1)O
Clinical Information
– Phase 3
Research Area
– Cardiovascular Disease
Solubility
– DMSO : ≥ 100 mg/mL
Target
– CETP
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.